Filing Flows

Filing Flows › United Guardian (UG) › Q3 2025

United Guardian (UG) Q3 2025 earnings results (third quarter 2025)

10-Q filed Nov 6, 2025

United Guardian (UG) reported revenue of $2.3M for the third quarter 2025 (Q3 2025), -26% from a year earlier and -20% from the quarter before. Operating margin was 9.5%, net earnings $268K (11.9% of revenue).

Revenue$2.3M
Year over year-26%
Quarter over quarter-20%
Operating margin9.5%
Net earnings$268K

United Guardian, Q3 2025: revenue $2.3M (-26% year over year), operating margin 9.5%, net earnings $268K, operating cash flow $1.0M. The chart follows the revenue to costs, profit and cash.

Q3 2025AmountQ/QY/Y
Revenue$2.3M-20%-26%
Operating profit$215K-69%-77%
Net earnings$268K-57%-69%
Operating cash flow$1.0M+233%-18%
Free cash flow$996K+249%-17%

What changed

Revenue was $2.3M in Q3 2025, down 26% year over year and down 20% from the previous quarter. Pharmaceuticals was the largest line at 54% of revenue. Cosmetic Ingredients lost $886K year over year (down 69%), 111% of the total change.

Operating profit was $215K, a 9.5% margin (down 21.5 points year over year). Total costs fell 3% while revenue fell 26%. Net earnings were $268K, down 69% year over year. The effective tax rate was 17.8%. Non-operating items added $111K, 34% of pre-tax earnings, so the bottom line overstates operating performance.

Operating cash flow was $1.0M (down 18% year over year), 377% of net earnings. Non-cash charges added back $27K of depreciation and amortization. Working capital and other items added $715K. Capital expenditures of $15K left free cash flow of $1.0M.

Questions

What was United Guardian's revenue in the third quarter 2025?

United Guardian (UG) reported revenue of $2.3M for the third quarter 2025 (Q3 2025), -26% from a year earlier and -20% from the quarter before.

Was United Guardian profitable in the third quarter 2025?

Operating profit was $215K (9.5% of revenue) and net earnings $268K.

Open the interactive Sankey →

Source: United Guardian 10-Q on SEC EDGAR.